Tags

Type your tag names separated by a space and hit enter

Long-term follow-up of antithrombotic management patterns in acute coronary syndrome patients.
Turk Kardiyol Dern Ars. 2018 04; 46(3):175-183.TK

Abstract

OBJECTIVE

The aim of this study was to evaluate the longterm, post-discharge follow-up of antithrombotic management patterns (AMPs), clinical outcomes, and real-life health status of patients hospitalized acute coronary syndrome (ACS).

METHODS

A total of 1034 patients hospitalized for ACS within 24 hours of symptom onset who survived to discharge were included. Of those, 514 had ST-segment elevation myocardial infarction (STEMI) and 520 had unstable angina (UA)/non-STEMI (NSTEMI). Data on follow-up AMPs, clinical outcomes, and health status were collected during 24 months of follow-up.

RESULTS

The overall all-cause mortality was 6.4% (6.7% in UA/NSTEMI and 6.0% in STEMI patients), cardiovascular (CV) events had occurred in 9.4% (9.8% in UA/NSTEMI and 8.9% in STEMI patients), and bleeding events in 2.0% (2.3% in STEMI and 1.7% in UA/NSTEMI patients) of patients at 2 years after discharge. EuroQol-visual analogue scales scores increased from 78.9 to 81.6 in STEMI patients, and from 76.0 to 76.2 in UA/NSTEMI patients. Discharge and 2-year postdischarge scores for the EuroQol-5D index were 0.7 and 0.9, respectively in STEMI patients, while it was 0.8 for each period in UA/STEMI patients. Overall, 57.5% of the patients on dual antiplatelet (AP) therapy at discharge remained on this treatment at 2 years after discharge. The use of 1AP/0 anticoagulant (AC) and ≥2AP/0AC were associated with a CV event risk of 10.5% and 8.9%, a mortality risk of 10.5% and 5.8%, and a bleeding event risk of 0.9% and. 2.2%, respectively.

CONCLUSION

These findings in a real-life population of ACS patients emphasize the importance of longer-term follow-up of ACS patients surviving hospitalization and support the likelihood of more favorable long-term outcomes in ACS management with the current treatment practices.

Authors+Show Affiliations

Department of Cardiology, Ankara University Faculty of Medicine, Ankara, Turkey. fs.ertas@gmail.com.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

29664423

Citation

Ertaş, Fatih Sinan, et al. "Long-term Follow-up of Antithrombotic Management Patterns in Acute Coronary Syndrome Patients." Turk Kardiyoloji Dernegi Arsivi : Turk Kardiyoloji Derneginin Yayin Organidir, vol. 46, no. 3, 2018, pp. 175-183.
Ertaş FS, Tokgozoglu L, EPICOR Study Group. Long-term follow-up of antithrombotic management patterns in acute coronary syndrome patients. Turk Kardiyol Dern Ars. 2018;46(3):175-183.
Ertaş, F. S., & Tokgozoglu, L. (2018). Long-term follow-up of antithrombotic management patterns in acute coronary syndrome patients. Turk Kardiyoloji Dernegi Arsivi : Turk Kardiyoloji Derneginin Yayin Organidir, 46(3), 175-183. https://doi.org/10.5543/tkda.2017.66724
Ertaş FS, Tokgozoglu L, EPICOR Study Group. Long-term Follow-up of Antithrombotic Management Patterns in Acute Coronary Syndrome Patients. Turk Kardiyol Dern Ars. 2018;46(3):175-183. PubMed PMID: 29664423.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Long-term follow-up of antithrombotic management patterns in acute coronary syndrome patients. AU - Ertaş,Fatih Sinan, AU - Tokgozoglu,Lale, AU - ,, PY - 2018/4/18/entrez PY - 2018/4/18/pubmed PY - 2018/9/28/medline SP - 175 EP - 183 JF - Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir JO - Turk Kardiyol Dern Ars VL - 46 IS - 3 N2 - OBJECTIVE: The aim of this study was to evaluate the longterm, post-discharge follow-up of antithrombotic management patterns (AMPs), clinical outcomes, and real-life health status of patients hospitalized acute coronary syndrome (ACS). METHODS: A total of 1034 patients hospitalized for ACS within 24 hours of symptom onset who survived to discharge were included. Of those, 514 had ST-segment elevation myocardial infarction (STEMI) and 520 had unstable angina (UA)/non-STEMI (NSTEMI). Data on follow-up AMPs, clinical outcomes, and health status were collected during 24 months of follow-up. RESULTS: The overall all-cause mortality was 6.4% (6.7% in UA/NSTEMI and 6.0% in STEMI patients), cardiovascular (CV) events had occurred in 9.4% (9.8% in UA/NSTEMI and 8.9% in STEMI patients), and bleeding events in 2.0% (2.3% in STEMI and 1.7% in UA/NSTEMI patients) of patients at 2 years after discharge. EuroQol-visual analogue scales scores increased from 78.9 to 81.6 in STEMI patients, and from 76.0 to 76.2 in UA/NSTEMI patients. Discharge and 2-year postdischarge scores for the EuroQol-5D index were 0.7 and 0.9, respectively in STEMI patients, while it was 0.8 for each period in UA/STEMI patients. Overall, 57.5% of the patients on dual antiplatelet (AP) therapy at discharge remained on this treatment at 2 years after discharge. The use of 1AP/0 anticoagulant (AC) and ≥2AP/0AC were associated with a CV event risk of 10.5% and 8.9%, a mortality risk of 10.5% and 5.8%, and a bleeding event risk of 0.9% and. 2.2%, respectively. CONCLUSION: These findings in a real-life population of ACS patients emphasize the importance of longer-term follow-up of ACS patients surviving hospitalization and support the likelihood of more favorable long-term outcomes in ACS management with the current treatment practices. SN - 1308-4488 UR - https://www.unboundmedicine.com/medline/citation/29664423/Long_term_follow_up_of_antithrombotic_management_patterns_in_acute_coronary_syndrome_patients_ L2 - https://www.journalagent.com/pubmed/linkout.asp?ISSN=1016-5169&PMID=29664423 DB - PRIME DP - Unbound Medicine ER -